Review article

cancer; thromboembolism; anticoagulant therapy; prevention

Luka Simetić

Abstract

Malignancies are associated with an increased risk of thromboembolic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Hypercoagulable state is the main occurrence of malignant diseases. In addition to the malignant cells that secrete procoagulant factors, the hypercoagulable state is also influenced by the patient’s own characteristics (excess weight, diabetes, arterial hypertension, etc.), as well as the specific oncology therapy applied. The pre- and postoperative risk of thromboembolism is increased in patients with malignant diseases who undergo surgical treatment. In the treatment of thromboembolic events in patients with malignant diseases, low molecular weight heparins (LMWH) and DOACs are mainly used. Paradoxically, in addition to the increased risk of thromboembolic events, patients with malignant diseases also have an increased risk of treatment-related bleeding. An individual approach to the patient with a malignant disease is required, taking into account their underlying malignant disease, comorbidities and risks, in order to maximally protect him from thrombosis and minimize the risk of bleeding.

Keywords

cancer; thromboembolism; anticoagulant therapy; prevention

Hrčak ID:

321770

URI

https://hrcak.srce.hr/321770

Publication date:

24.10.2024.

Article data in other languages: croatian

Visits: 0 *